Sarcoma News and Research

RSS

First-in-class experimental CAR T-cell therapy shows promise against solid tumors

Researchers with the Charbonneau Cancer Institute at the University of Calgary and McMaster University have identified a unique target present on a specific group of solid cancerous tumors.

2 Jul 2026

Dual-target CAR-T therapy shows promise against aggressive brain tumors

Researchers at McMaster University have developed a new cancer immunotherapy strategy that can simultaneously attack deadly brain tumors and the immune cells that help them grow.

1 Jul 2026

Gene fusion patterns refine classification of rare acute leukemias

Acute leukemias with chimeric fusion genes involving FET (FUS, EWSR1, and TAF15) family proteins and ETS (E26 transformation-specific)-like transcription factors often present with unique clinical and pathological characteristics.

27 Jun 2026

Targeting metabolic pathways could prevent relapse in KRAS-mutant cancers

Our cells rely on tightly regulated signaling pathways to control when they grow, divide, and survive. When these regulatory systems are disrupted, cells can acquire the ability to grow uncontrollably and become cancerous.

25 Jun 2026

Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering

The University of Oklahoma has received an $11.5 million award from the National Institutes of Health to establish the Oklahoma Center of ImmunoEngineering, a new research center designed to accelerate the study and treatment of diseases rooted in the immune system.

12 Jun 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026

New funding supports cutting-edge research to combat cancers across South Texas

The University of Texas at San Antonio (UT San Antonio) and its academic health center, UT Health San Antonio, recently received over $2.7 million in new academic and prevention awards from the Cancer Prevention and Research Institute of Texas (CPRIT) to further its mission of combating cancers across South Texas.

2 Jun 2026

Scientists reveal why common pancreatic precancer lesions rarely turn deadly

Spatial and single-cell analyses of human donor pancreata showed that PanIN epithelial cells gradually acquire cancer-like molecular features, while their surrounding stromal and immune environment remains closer to normal pancreatic tissue. The findings suggest that delayed or incomplete microenvironmental reprogramming may help explain why most PanIN lesions remain indolent rather than progressing to pancreatic cancer.

24 May 2026

New biomarker predicts therapy response for hard-to-treat childhood cancers

A study by researchers at the University of Birmingham has identified a new biomarker for response to a specific cancer therapy, treating children with Ewing Sarcoma and other tumor types.

22 May 2026

Specific gene fusion patterns tied to solitary fibrous tumor outcomes

Specific genetic fusion patterns in solitary fibrous tumors may help identify which patients face a higher risk of metastasis, recurrence and more aggressive disease behavior, according to new research that could improve how physicians assess and eventually treat this rare cancer.

21 May 2026

Scientists find unexpected immune pathways for mRNA cancer vaccines

The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic.

17 Apr 2026

Scientists discover BRCA links to head and neck cancer risks

An international group led by researchers from the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have discovered associations between pathogenic variants of the BRCA 1 and 2 genes and four types of cancer. Published in ESMO Open, the findings expand the potential for personalized medicine to several cancer types that currently have limited treatment options and poor prognoses.

17 Apr 2026

ESMO and EURACAN call for policy action to standardize care for patients with rare cancers

Adherence to Clinical Practice Guidelines in the management of rare cancers remains inconsistent across Europe despite demonstrably improving patient outcomes, shows an analysis jointly conducted by ESMO and EURACAN, the European Reference Network (ERN) for rare cancers.

13 Mar 2026

Using engineered bacteria to breach tumor defenses

Baylor University researchers have published a novel approach to fight colorectal cancer, using modified bacteria as a courier to deliver potent cancer-killing proteins into tumor cells. Michael S. VanNieuwenhze, Ph.D., FRSC, University Distinguished Professor and chair of the Department of Biology, along with Baylor doctoral students and a colleague at Texas Tech University Health Sciences Center, published their promising research in Cell Chemical Biology.

10 Mar 2026

How somatic mutations shape disease and reveal new drug targets

Researchers reviewed how somatic mutations accumulate in normal and diseased tissues, showing that natural selection can expand clones that influence disease risk, tissue adaptation, or cellular resilience. The study proposes somatic genomics as a powerful strategy to uncover disease mechanisms and identify new therapeutic targets across multiple conditions.

8 Mar 2026

Targeting glutamine metabolism offers new hope for synovial sarcoma treatment

Synovial sarcoma is an aggressive malignant tumor that primarily affects the limbs of teenagers and young adults.

26 Feb 2026

NCCN publishes new guidelines for management of pediatric soft tissue sarcomas

The National Comprehensive Cancer Network (NCCN) today published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Soft Tissue Sarcomas.

17 Feb 2026

Childhood cancer survival varies by tumor stage at diagnosis

A major study by UCL and Fondazione IRCCS Istituto Nazionale dei Tumori in Milan (INT) researchers has for the first time shown in detail how far children's cancer has spread at diagnosis in a way that can be compared between countries.

9 Feb 2026

Novel cryo-EM findings could revolutionize T cell immunotherapy design

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack dangerous cells. Yet a full understanding of how they actually work has eluded researchers.

16 Dec 2025